FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382806752> ?p ?o ?g. }

• W4382806752 endingPage "S11" @default.
• W4382806752 startingPage "S11" @default.
• W4382806752 abstract "Associated with a poor prognosis, there is an increased medical need for BRAFV600E-mutant metastatic colorectal cancer (mCRC) patients for improved therapeutic approaches. Upon completion of the BEACON CRC-trial, targeted treatment (TT) with encorafenib plus cetuximab (E+C) after prior systemic therapy is now regarded as a standard of care for these patients. Since clinical data from controlled clinical trials is limited and based on a selected patient population, the non-interventional study (NIS) BERINGCRC aims to observe a broader patient population in current clinical practice. BERINGCRC is the first NIS evaluating clinical practices in the use of E+C after prior systemic therapy according to the approved respective Summary of Product Characteristics (SmPC) in BRAFV600E-mutant mCRC patients in Germany, Austria, and Switzerland. BERINGCRC is ongoing and aims to enroll up to 300 patients from 126 sites. For the present analysis, disease characteristics and treatment data of the first 120 patients were collected at 56 sites across Germany, Austria, and Switzerland between 09/2020 and 11/2022. Consistent with BEACON CRC, adjuvant systemic therapy with relapse ≤ 6 months was counted as metastatic 1st-line treatment. The primary endpoint is the 1-year overall survival rate. Secondary endpoints include efficacy, QoL, and tolerability of E+C. A total of 120 patients was included in this analysis. Median age was 66.4 years (range 31 to 88) and approximately half of the patients (51.7%) were male. 68 patients (56.7%) were documented with right-sided tumors and for 60.0% of the patients stage IV disease was noted when the primary diagnosis was established. In the metastatic setting, main sites of metastasis were liver, peritoneum, and lung (50.8%, 32.5%, and 20.8% of the patients, respectively), with 13.3% of the patients presenting with ≥ 3 metastatic sites. For 30.8% of the patients, an ECOG performance status (PS) of 0 was documented at baseline (ECOG PS 1: 46.7%; ECOG PS 2: 8.3%; ECOG PS 3: 1.7%; Not done/missing: 12.5%). Evaluable treatment details were documented in 103 patients. Treatment in adjuvant setting was reported for 33 patients (32.0%). Thirty one (93.9%) of these patients received chemotherapy alone. Early relapse in adjuvant setting was documented for 15 of them (45.5%). In first line, 9 (8.7%) were documented with E+C treatment directly following adjuvant therapy. Another 48.5% of the patients received chemotherapy alone, for 39.8% chemotherapy was combined with targeted therapy, 1.0% received immunotherapy, and 1.0% received targeted therapy alone. In second line, 69.9% of the patients with documented treatment received E+C, 9.7% were treated with chemotherapy alone, and 11.7% with chemotherapy + targeted therapy. An initial bi-weekly cetuximab dosing was reported for 8.7% of the patients treated with E+C. In line with previous findings on BRAFV600E-mutant mCRC patients, the number of patients with right-sided tumors was relatively high. However, compared to literature, synchronous metastases were reported considerably more often in this NIS. Compared to the pivotal study BEACON CRC, BERINGCRC patients were notably older and less patients were documented with ECOG PS 0." @default.
• W4382806752 created "2023-07-02" @default.
• W4382806752 creator A5008118991 @default.
• W4382806752 creator A5010300546 @default.
• W4382806752 creator A5013636749 @default.
• W4382806752 creator A5022175582 @default.
• W4382806752 creator A5028841026 @default.
• W4382806752 creator A5034847353 @default.
• W4382806752 creator A5036078463 @default.
• W4382806752 creator A5043273368 @default.
• W4382806752 creator A5045314322 @default.
• W4382806752 creator A5047374036 @default.
• W4382806752 creator A5052808201 @default.
• W4382806752 creator A5053589015 @default.
• W4382806752 creator A5063193304 @default.
• W4382806752 creator A5063566935 @default.
• W4382806752 creator A5071076758 @default.
• W4382806752 creator A5079085915 @default.
• W4382806752 creator A5079645039 @default.
• W4382806752 creator A5081829270 @default.
• W4382806752 creator A5087142746 @default.
• W4382806752 date "2023-06-01" @default.
• W4382806752 modified "2023-10-02" @default.
• W4382806752 title "PD-25 Disease characteristics and real-world treatment pathways of BRAF V600E-mutant metastatic colorectal cancer patients: Analysis of 120 patients enrolled in the BERING CRC study" @default.
• W4382806752 doi "https://doi.org/10.1016/j.annonc.2023.04.052" @default.
• W4382806752 hasPublicationYear "2023" @default.
• W4382806752 type Work @default.
• W4382806752 citedByCount "0" @default.
• W4382806752 crossrefType "journal-article" @default.
• W4382806752 hasAuthorship W4382806752A5008118991 @default.
• W4382806752 hasAuthorship W4382806752A5010300546 @default.
• W4382806752 hasAuthorship W4382806752A5013636749 @default.
• W4382806752 hasAuthorship W4382806752A5022175582 @default.
• W4382806752 hasAuthorship W4382806752A5028841026 @default.
• W4382806752 hasAuthorship W4382806752A5034847353 @default.
• W4382806752 hasAuthorship W4382806752A5036078463 @default.
• W4382806752 hasAuthorship W4382806752A5043273368 @default.
• W4382806752 hasAuthorship W4382806752A5045314322 @default.
• W4382806752 hasAuthorship W4382806752A5047374036 @default.
• W4382806752 hasAuthorship W4382806752A5052808201 @default.
• W4382806752 hasAuthorship W4382806752A5053589015 @default.
• W4382806752 hasAuthorship W4382806752A5063193304 @default.
• W4382806752 hasAuthorship W4382806752A5063566935 @default.
• W4382806752 hasAuthorship W4382806752A5071076758 @default.
• W4382806752 hasAuthorship W4382806752A5079085915 @default.
• W4382806752 hasAuthorship W4382806752A5079645039 @default.
• W4382806752 hasAuthorship W4382806752A5081829270 @default.
• W4382806752 hasAuthorship W4382806752A5087142746 @default.
• W4382806752 hasBestOaLocation W43828067521 @default.
• W4382806752 hasConcept C121608353 @default.
• W4382806752 hasConcept C126322002 @default.
• W4382806752 hasConcept C143998085 @default.
• W4382806752 hasConcept C197934379 @default.
• W4382806752 hasConcept C203092338 @default.
• W4382806752 hasConcept C2778375690 @default.
• W4382806752 hasConcept C2779998722 @default.
• W4382806752 hasConcept C2908647359 @default.
• W4382806752 hasConcept C526805850 @default.
• W4382806752 hasConcept C535046627 @default.
• W4382806752 hasConcept C71924100 @default.
• W4382806752 hasConcept C99454951 @default.
• W4382806752 hasConceptScore W4382806752C121608353 @default.
• W4382806752 hasConceptScore W4382806752C126322002 @default.
• W4382806752 hasConceptScore W4382806752C143998085 @default.
• W4382806752 hasConceptScore W4382806752C197934379 @default.
• W4382806752 hasConceptScore W4382806752C203092338 @default.
• W4382806752 hasConceptScore W4382806752C2778375690 @default.
• W4382806752 hasConceptScore W4382806752C2779998722 @default.
• W4382806752 hasConceptScore W4382806752C2908647359 @default.
• W4382806752 hasConceptScore W4382806752C526805850 @default.
• W4382806752 hasConceptScore W4382806752C535046627 @default.
• W4382806752 hasConceptScore W4382806752C71924100 @default.
• W4382806752 hasConceptScore W4382806752C99454951 @default.
• W4382806752 hasLocation W43828067521 @default.
• W4382806752 hasOpenAccess W4382806752 @default.
• W4382806752 hasPrimaryLocation W43828067521 @default.
• W4382806752 hasRelatedWork W1908989187 @default.
• W4382806752 hasRelatedWork W2313360580 @default.
• W4382806752 hasRelatedWork W2435704186 @default.
• W4382806752 hasRelatedWork W2439403919 @default.
• W4382806752 hasRelatedWork W2588306759 @default.
• W4382806752 hasRelatedWork W2589204743 @default.
• W4382806752 hasRelatedWork W2729289325 @default.
• W4382806752 hasRelatedWork W2908163567 @default.
• W4382806752 hasRelatedWork W2944268665 @default.
• W4382806752 hasRelatedWork W3026015583 @default.
• W4382806752 hasVolume "34" @default.
• W4382806752 isParatext "false" @default.
• W4382806752 isRetracted "false" @default.
• W4382806752 workType "article" @default.